Davita statement on glp-1 and potential implications on chronic kidney disease

Denver , oct. 12, 2023 /prnewswire/ -- davita issued the following statement in response to news this week from novo nordisk, manufacturer of ozempic®, a glucagon-like peptide 1 (glp-1) receptor agonist indicated for type 2 diabetes, related to its flow study that sought to demonstrate that ozempic delays progression of chronic kidney disease (ckd) and lowers the risk of kidney and cardiovascular mortality. the following statement can be attributed to dr. jeff giullian, chief medical officer for davita inc. "we've been closely monitoring the developments related to glp-1s, and are excited about the potential benefits this class of drugs could have on society and patients with kidney disease.
DVA Ratings Summary
DVA Quant Ranking